Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: Prognostic and predictive significance

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Grisanti, Salvatore ^a   Almici, Camillo ^b   Consoli, Francesca ^a   Buglione, Michela ^a   Verardi, Rosanna ^b   Bolzoni Villaret, Andrea ^a   Bianchetti, Andrea ^b   Ciccarese, Chiara ^a   Mangoni, Monica ^c   Ferrari, Laura ^a   Biti, Gianpaolo ^c   Marini, Mirella ^b   Ferrari, Vittorio D ^a   Nicolai, Piero ^a   Magrini, Stefano M ^a   Berruti, Alfredo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; METABOLISM; METASTASIS; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RISK; TUMOR EMBOLISM;

DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; ODDS RATIO; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84905660835     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103918     Document Type: Article

References (33)

1. Pignon JP, Le Maitre A, Bourhis J (2007) Meta-analyses of chemotherapy in head and neck (MACH-NC): an update. Int J Rad Oncol Biol Phys 69: s112-s114.
2. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21: vii252-vii261.
3. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ (2004) Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Sem Radiat Oncol 14: 190-195. (Pubitemid 38586112)
4. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
5. Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101: 2222-2229.
6. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29: 1556-1563.
7. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791. (Pubitemid 39095313)
8. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221.
9. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309.
10. Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35: 463-474.
11. Partridge M, Brakenhoff R, Phillips E, Kulsan A, Francis R, et al. (2003) Detection of rare disseminated tumor cells identifies head and neck cancer patients at risk of treatment failure. Clin Cancer Res 9: 5287-5294. (Pubitemid 37413581)
12. Wirtschafter A, Benninger MS, Moss TJ, Umiel T, Blazoff K, et al. (2002) Micrometastatic tumor detection in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 128: 40-43. (Pubitemid 34052082)
13. Tong X, Yang L, Campbell Lang J, Zborowski M, Chalmers JJ (2007) Application of immunomagnetic cell enrichment in combination with RT-PCR for the detection of rare circulating head and neck tumor cells in human peripheral blood. Cytometry Part B (Clinical Cytometry) 72B: 310-323. (Pubitemid 350194348)
14. Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, et al. (2010) Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck. Arch Otol Head Neck Surg 136: 1274-1279.
15. Hristozova T, Konschak R, Stromberger C, Fusi A, Liu Z, et al. (2011) The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in unresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol 22: 1878-1885.
16. Went PTH, Lugli A, Maier S, Bundi M, Mirlacher M, et al. (2004) Frequent EpCAM protein expression in human carcinomas. Human Pathology 35: 122-128. (Pubitemid 38133932)
17. Laimer K, Fong D, Gastl G, Obrist P, Kloss F, et al. (2008) EpCAM expression in squamous cell carcinoma of the oral cavity: frequency and relationship to clinicopathologic features. Oral Oncol 44: 72-77. (Pubitemid 350251282)
18. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, et al. (2009) Circulating tumor cells as a diagnostic marker in primary lung cancer. Clin Cancer Res 15: 6980-6986.
19. Buglione M, Grisanti S, Almici C, Mangoni M, Polli C, et al. (2012) Circulating tumor cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. Eur J Cancer 48: 3019-3026.
20. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, et al. (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant disease. Clin Cancer Res 10: 6897-6904. (Pubitemid 39383039)
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion, et al. (2005) Reporting recommendations for tumor markers prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184. (Pubitemid 41258223)
22. Nichols AC, Lowes LE, Szeto CCT, Basmaji J, Dhaliwal S, et al. (2012) Detection of circulating tumor cells in advanced head and neck cancer using the cellsearch system. Head Neck 34: 1440-1444.
23. Bozec A, Ilie M, Dassonville O, Elodie L, Poissonnet G, et al. (2013) Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 270: 2745-2749.
24. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, et al. (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11: R46. DOI: 10.1186/bcr2333.
25. Bleijerveld OB, Brakenhoff RH, Schaaij-Visser TB, Damen JM, Altelaar AF, et al. (2011) Protein signatures associated with tumor cell dissemination in head and neck cancer. J Proteomics 74: 558-566.
26. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, et al. (2009) Tumor self-seeding by circulating tumor cells. Cell 139: 1315-1326.
27. Gazzaniga P, Gradilone A, Naso G, Cortesi E, Gianni W, et al. (2008) Chemoresistance profile of circulating tumor cells: toward a clinical benefit? Int J Cancer 123: 1730-1732.
28. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, et al. (1998) Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832. (Pubitemid 28280548)
29. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, et al. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356. (Pubitemid 36025259)
30. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, et al. (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118: 523-530.
31. Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326. (Pubitemid 44449137)
32. Licitra L, Storkel S, Ferr KM, Van Cutsem E, Pirker R, et al. (2013) Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 49: 1161-1168.
33. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, et al. (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22: 1078-1087.